Atossa Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$37.7MTTM through 30 Jun 2026
Free Cash Flow -$35.8MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-123.0%ROE
-99.0%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio4.92x
Net Debt-$31.7Mnet cash position
Cash & Equivalents$26.1M
Quality Metrics
Altman Z-Score-12.06
Piotroski F-Score2 / 9
Earnings-Beat Rate25.0%
Multi-Year Trend
Diluted EPS-$4.34TTMFY2025: $-4.04
Dividend
No dividend
Capital Allocation
R&D Spend$21.2M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Oncology and Rare Diseases | $0 | View detailsFocusing on clinical development of (Z)-endoxifen in breast cancer and rare diseases such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.